Pianzihuang liver disease medication can't rise anymore 2025 annual report: Revenue down 16.56%, net profit down 27.49% Shareholders dropped from 283,000 to 129,900, northbound holdings fell from 8.7% to 2.3%. I think it's funny, a few years ago Pianzihuang was hard to get, scalpers could make hundreds per batch, and now?